Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aimed to compare the efficacy of misoprostol versus intravaginal Evening Primrose Oil capsule as a cervical ripening agent prior to operative hysteroscopy.
Hysteroscopy is an operative procedure in which the gynaecologist directly examines the uterine cavity using a small telescopic instrument (hysteroscope) inserted via the vagina and the cervix.
Misoprostol is a synthetic Prostaglandins (PGE1) analogue that has been found to be a safe and inexpensive agent for cervical ripening. It is one of the most studied cervical ripening agents used prior to hysteroscopy.
Evening primrose oil is derived from the seeds of the evening primrose (Oenothera biennis) plant. It is rich in the essential fatty acid gamma linolenic acid, a fatty acid that the body converts to a hormone like substance called prostaglandin E1.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group I | Experimental | Patients received evening Primorose Oil. |
|
| Group II | Experimental | Patients received Misoprostol. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Primorose Oil | Other | Patients received evening Primorose Oil. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of cervical Ripening | Cervical ripening assessed by the interval between insertion of Hegar dilators size 3 and size 10, and by the size of the first Hegar dilator requiring forceful insertion. | During operative hysteroscopy (2 hours after vaginal administration of the study medication) |
| Measure | Description | Time Frame |
|---|---|---|
| Cervical Bleeding | Occurrence of cervical bleeding during cervical entry was recorded. | During operative hysteroscopy (2 hours after vaginal administration of the study medication) |
| False Passage Formation |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Women underwent Hysteroscopy
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sohag University | Sohag | 82511 | Egypt |
The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
After the end of study for one year.
The data will be available upon a reasonable request from the corresponding author.
Not provided
Not provided
| ID | Term |
|---|---|
| D016595 | Misoprostol |
| ID | Term |
|---|---|
| D011459 | Prostaglandins E, Synthetic |
| D011465 | Prostaglandins, Synthetic |
| D011453 | Prostaglandins |
| D015777 | Eicosanoids |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Misoprostol |
| Other |
Patients received Misoprostol. |
|
Occurrence of false passage during cervical instrumentation was recorded.
| During operative hysteroscopy (2 hours after vaginal administration of the study medication) |
| Cervical Laceration | Occurrence of cervical laceration during cervical dilatation was recorded. | During operative hysteroscopy (2 hours after vaginal administration of the study medication) |
| Incidence of drug-related adverse effects | Incidence of drug-related adverse effects such as the occurrence of nausea, vomiting, diarrhea, fever, and severe abdominal pain were recorded. | Until completion of the procedure (Up to 2 hours) |
| D005231 |
| Fatty Acids, Unsaturated |
| D005227 | Fatty Acids |
| D008055 | Lipids |
| D012898 | Autacoids |
| D018836 | Inflammation Mediators |
| D001685 | Biological Factors |